Tag: licensing
-
Cancer Immunotherapy Biotech Issues $80M IPO
A biotechnology company designing immunotherapies for solid tumor cancers with a patient’s white blood cells is raising $80 million in its initial public offering or IPO.
-
One-Time Crispr HIV Therapy Given Fast-Track Status
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration.
-
Trial Underway Testing Dried Plasma for Transfusions
A clinical trial is recruiting participants to assess the safety and feasibility of a system for spray drying and re-constituting a person’s blood plasma.
-
Patent Issued for Synthetic Peptide Chain Techniques
A new U.S. patent, licensed to a start-up biotechnology company, describes processes for linking together chains of synthetic peptides into therapeutic proteins.
-
Companies Partner on A.I., Fusion Energy for Space Flight
A developer of fusion energy for space travel and software company for space flight systems are writing machine learning algorithms to design a hyper-fast rocket engine.
-
Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds.
-
Pharma Company Gains Precise Gene Edits in $2B Biotech Deal
A global drug maker is acquiring access to a biotechnology company’s precise genome editing techniques to develop new therapies for rare and cardiometabolic disorders.
-
Measles-Rubella Patch Vaccine Shown Effective as Injection
A clinical trial shows a peel-and-stick patch device is as effective as a standard syringe injection in delivering a vaccine that protects against measles and rubella.
-
Moderna, Biotech Partner on Non-Viral Genetic Drug Delivery
Two biotechnology companies are collaborating on creating genetic therapies delivered with lipid nanoscale particles using non-viral mechanisms to reach target cells.
-
Start-Up Licenses Protein Therapy Tech, Raises $50M
A new company making antibodies that degrade disease-causing proteins on and outside cell surfaces is raising $50 million in its first venture funding round.